Syndax Pharmaceuticals Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos's Lirentelimab Flunks Late-Stage Studies In Patients With Inflammation In Digestive Tract Alla

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos''s Lirentelimab Flunks Late-Stage Studies In Patients With Inflammation In Digestive Tract Allakos, Inc. (NASDAQ: ALLK ) announced data from ENIGMA 2 Phase 3 study of lirentelimab in patients with biopsy confirmed eosinophilic gastritis and/or eosinophilic duodenitis and KRYPTOS Phase 2/3 study of lirentelimab in patients with biopsy-confirmed eosinophilic esophagitis. Both ENIGMA 2 and KRYPTOS studies met their histologic co-primary endpoints, but did not achieve statistical significance on the patient reported symptomatic co-primary endpoints. The stock was down 7.69% to $77.90 in premarket trading. FDA Imposes Clinical Hold On Injectable Form Of Gilead''s HIV Drug Candidate Due to Concerns Over Vial Quality Gilead Sciences, Inc. (NASDAQ: GILD ) announced that the U.S. Food and Drug Administration has placed a clinical hold on the use of injectable lenacapavir in borosilicate vials in all ongoing clinical studies for HIV treatment and HIV pre-exposure prophylaxis.

Protagonist Therapeutics (NASDAQ:PTGX) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings. Profitability This table compares Protagonist Therapeutics and Syndax Pharmaceuticals net margins, return on equity and []

Related Stocks: SNDX ,

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has earned an average recommendation of Buy from the six analysts that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month target price among analysts that have covered []

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug Calliditas Therapeutics AB (

Related Stocks: SNDX ,

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) gapped up prior to trading on Tuesday . The stock had previously closed at $16.53, but opened at $17.85. Syndax Pharmaceuticals shares last traded at $17.84, with a volume of 5,347 shares trading hands. A number of analysts recently issued reports on the company. Zacks Investment Research lowered Syndax Pharmaceuticals from […]

Syndax Pharmaceuticals Inc (NASDAQ: SNDX ) revealed updated data from the Phase 1 dose-escalation portion of the AUGMENT-101 trial of SNDX-5613 in patients with mutant nucleophosmin (mNPM1) or mixed-lineage leukemia rearranged (MLLr) relapsed/refractory acute leukemias. The data were featured at the American Society of Hematology (ASH) Annual Meeting. Across evaluable patients with mNPM1 (n=13) or MLLr (n=38) who received at least one dose of SNDX-5613, the overall response rate (ORR) was 55%, with a complete Full story available on Benzinga.com

Syndax Pharmaceuticals Inc (NASDAQ: SNDX) revealed updated data from the Phase 1 dose-escalation portion of the AUGMENT-101 trial of SNDX-5613 in patients with mutant nucleophosmin (mNPM1) or mixed

Brokerages expect Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) to announce earnings per share (EPS) of ($0.68) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Syndax Pharmaceuticals earnings, with estimates ranging from ($0.74) to ($0.62). Syndax Pharmaceuticals posted earnings of ($0.44) per share in the same quarter last year, which indicates []

WALTHAM, Mass., Dec. 11, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated positive data from its Phase 1/2 trial of

WALTHAM, Mass., Dec. 9, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) announced today that the Hart-Scott-Rodino (HSR) antitrust waiting period had expired and that the parties closed the exclusive worldwide collaboration and license

Equities research analysts expect Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) to post earnings of ($0.68) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Syndax Pharmaceuticals earnings, with estimates ranging from ($0.74) to ($0.62). Syndax Pharmaceuticals reported earnings per share of ($0.44) in the same quarter last year, which []